CCM
PRCT icon

Chilton Capital Management’s Procept Biorobotics PRCT Stock Holding History

Chilton Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.82K Hold
125
– – ﹤0.01% 527
2026
Q1 		$3.13K Hold
125
– – ﹤0.01% 579
2025
Q4 		$3.93K Hold
125
– – ﹤0.01% 516
2025
Q3 		$4.46K Hold
125
– – ﹤0.01% 525
2025
Q2 		$7.2K Hold
125
– – ﹤0.01% 478
2025
Q1 		$7.28K Hold
125
– – ﹤0.01% 473
2024
Q4 		$10.1K Hold
125
– – ﹤0.01% 457
2024
Q3 		$10K Hold
125
– – ﹤0.01% 482
2024
Q2 		$7.64K Hold
125
– – ﹤0.01% 503
2024
Q1 		$6.18K Hold
125
– – ﹤0.01% 501
2023
Q4 		$5.24K Hold
125
– – ﹤0.01% 503
2023
Q3 		$4.1K Hold
125
– – ﹤0.01% 469
2023
Q2 		$4.42K Hold
125
– – ﹤0.01% 487
2023
Q1 		$3.55K Buy
+125
New +$4.41K ﹤0.01% 504
2022
Q3 		– Sell
-125
Closed -$4K – 522
2022
Q2 		$4K Buy
+125
New +$4.55K ﹤0.01% 559
2022
Q1 		– Sell
-125
Closed -$3K – 519
2021
Q4 		$3K Buy
+125
New +$4.62K ﹤0.01% 588

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Chilton Capital Management's PRCT Position: Q2 2026 in Review

Chilton Capital Management held its Procept Biorobotics (PRCT) position steady in Q2 2026 at 125 shares worth $2.82K. The position accounts for ﹤0.01% of the portfolio, ranked #527.

Chilton Capital Management first reported a position in PRCT in Q4 2021 and has held it in 16 quarters since. The position peaked at $10.1K in Q4 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Chilton Capital Management held 125 shares of Procept Biorobotics worth $2.82K as of Q2 2026.
  • Chilton Capital Management left its Procept Biorobotics share count unchanged in Q2 2026.
  • Procept Biorobotics made up ﹤0.01% of Chilton Capital Management's portfolio in Q2 2026, its #527 holding.
  • Chilton Capital Management first reported a position in Procept Biorobotics in Q4 2021 and has held it in 16 quarters since.
  • Chilton Capital Management's Procept Biorobotics position peaked at $10.1K in Q4 2024.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Chilton Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.